Transitional cell carcinoma metastatic – Life with Disease

Go back

Metastatic transitional cell carcinoma is a serious condition where cancer that started in the lining of the urinary system has spread to distant parts of the body such as lymph nodes, lungs, liver, or bones. Understanding what to expect with this advanced stage of cancer can help patients and their families prepare for the journey ahead and make informed decisions about care.

Prognosis: What to Expect with Metastatic Disease

When transitional cell carcinoma spreads beyond the kidney, ureter, or bladder to other organs, it is considered metastatic or stage IV disease. This is a difficult reality for patients and their loved ones to face, and it’s important to approach this topic with both honesty and compassion.[1]

The outlook for metastatic transitional cell carcinoma is significantly more limited compared to cancer caught at earlier stages. When the disease is superficial and confined to the original site—the renal pelvis or ureter—more than 90% of patients can be cured. However, when tumors have penetrated through the wall of the urinary tract or spread to distant organs, cure with currently available treatments is usually not possible.[6]

This does not mean that treatment has no value. The goal of therapy for metastatic disease shifts from trying to cure the cancer to prolonging survival, slowing the growth of tumors, easing symptoms, and improving quality of life. In other words, the focus becomes helping you live as well as you can for as long as you can.[23]

Patients with tumors that have penetrated through the urothelial wall—the specialized tissue lining parts of the urinary system—or with distant metastases face the most challenging prognosis. Current medical approaches can extend life and reduce discomfort, but complete elimination of the cancer is rare. It’s worth noting that in some uncommon cases, treatment of metastatic bladder cancer may result in a cure, though this is not the typical outcome.[10][23]

Statistical information about survival can feel overwhelming, but it’s important to remember that every person is different. Your individual response to treatment, overall health, age, and other factors all play a role in your personal journey. Median overall survival for metastatic urothelial cancer with standard chemotherapy is about 14 months, but some patients live longer, while others face a shorter timeline.[13]

⚠️ Important
If you have been diagnosed with metastatic transitional cell carcinoma, remember that prognosis statistics represent averages from many patients and cannot predict your individual outcome. Every person responds differently to treatment. It is essential to have open, honest conversations with your medical team about your specific situation, treatment options, and what you can expect.

Natural Progression Without Treatment

Understanding how metastatic transitional cell carcinoma behaves when left untreated helps explain why doctors recommend starting therapy even when cure is not possible. Without treatment, cancer cells continue to grow and multiply without restraint.[2]

Once transitional cell cancer has metastasized, it means cancer cells have traveled from their original location to other parts of the body. The most common sites where this cancer spreads include the pelvic lymph nodes—small bean-shaped structures that are part of the immune system—and organs such as the lungs, liver, and bones. In some cases, especially after patients have received chemotherapy, the cancer may also spread to the brain.[2]

In one documented case, a patient developed soft tissue masses in the shoulder area along with bone metastases in multiple locations including the scapula (shoulder blade), femur (thighbone), and pelvis. This unusual pattern shows that transitional cell carcinoma can spread to unexpected places.[2]

As the disease progresses without treatment, tumors grow larger and may cause increasing symptoms. Pain can develop as tumors press on nerves, bones, or other structures. Weight loss and fatigue often worsen as the cancer consumes the body’s resources and interferes with normal organ function. If the cancer spreads to the lungs, breathing may become difficult. Liver metastases can cause abdominal swelling and jaundice, a yellowing of the skin and eyes. Bone involvement often leads to severe pain and fractures.[2]

The speed at which untreated metastatic disease progresses varies from person to person. Some patients experience rapid deterioration within weeks to months, while others may have a slower course. Factors that influence progression include the tumor’s grade (how abnormal the cells look under a microscope), how many organs are involved, and the person’s overall health and age.[6]

Possible Complications

Metastatic transitional cell carcinoma can lead to a range of complications that affect both quality of life and survival. These complications can arise from the cancer itself, from its spread to various organs, or as side effects of treatment.[2]

When cancer spreads to bones, it can cause severe pain that may be difficult to control even with strong pain medications. Bone metastases also weaken the bone structure, making fractures more likely even from minor injuries or normal activities. In the case described in medical literature, a patient developed metastatic disease in the right scapula, both femurs, and parts of the pelvis.[2]

Soft tissue metastases, though less common, can also occur. One patient developed palpable masses in the shoulder area that could be felt through the skin. These masses caused significant shoulder and neck pain that interfered with daily activities.[2]

Lung metastases can lead to shortness of breath, persistent cough, and chest pain. As tumors grow in the lungs, they reduce the amount of healthy lung tissue available for breathing, which can make even simple activities exhausting. Liver involvement may cause abdominal pain, swelling, jaundice, and loss of appetite. The liver plays a crucial role in filtering toxins from the blood, so when it’s compromised by cancer, patients may feel generally unwell.[2]

Lymph node involvement can cause swelling and discomfort, particularly in the pelvic area. Enlarged lymph nodes may press on blood vessels or other structures, potentially causing additional complications such as leg swelling or blood clots.[2]

Treatment-related complications are also a concern. Chemotherapy, which is commonly used for metastatic disease, can cause numerous side effects including nausea, vomiting, diarrhea, loss of appetite, mouth sores, anemia, and increased risk of infections. In one documented case, a patient receiving chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin experienced such severe toxicity—including febrile urinary tract infections and aphthous ulcers (painful mouth sores)—that treatment had to be discontinued.[2]

Kidney function often declines in patients with transitional cell carcinoma, particularly if surgery has been performed or if both kidneys are affected. Reduced kidney function limits the types of chemotherapy that can be safely given. Up to 50% of patients with metastatic urothelial cancer are ineligible for cisplatin-based chemotherapy, which is considered the most effective treatment, because their kidneys cannot handle this medication.[13]

Rapid weight loss is another common complication. In the case study referenced, a patient experienced rapid weight loss just weeks after starting salvage chemotherapy, ultimately requiring hospitalization.[2]

Emotional and psychological complications should not be overlooked. Depression, anxiety, and fear are common and completely understandable responses to a diagnosis of metastatic cancer. These mental health challenges can affect appetite, sleep, energy levels, and overall quality of life.[3]

Impact on Daily Life

Living with metastatic transitional cell carcinoma affects virtually every aspect of daily life, from physical abilities to emotional well-being, relationships, work, and leisure activities. Understanding these impacts can help patients and families prepare and find ways to cope.[3]

Physical limitations often become increasingly noticeable as the disease progresses or during treatment. Fatigue is one of the most common and challenging symptoms. This is not ordinary tiredness that improves with rest—it’s a profound exhaustion that can make even simple tasks like getting dressed or preparing a meal feel overwhelming. Many patients find they need to pace themselves carefully, choosing which activities are most important and accepting that they cannot do everything they once did.[3]

Pain can significantly interfere with daily activities. Whether from bone metastases, soft tissue involvement, or treatment side effects, pain may limit mobility and make it difficult to find comfortable positions for sitting, lying down, or sleeping. Pain management becomes a daily focus, requiring careful coordination with healthcare providers to find the right combination of medications and other strategies.[2]

Blood in the urine, which is a common symptom of transitional cell carcinoma, can be distressing and may require frequent bathroom trips. Painful or frequent urination adds another layer of disruption to daily routines and can make leaving home anxiety-provoking.[3]

Treatment schedules often dominate the calendar. Chemotherapy appointments, blood tests to monitor side effects, imaging scans to check disease progression, and visits to multiple specialists consume significant time and energy. The need for frequent medical appointments can make it difficult or impossible to maintain employment or keep up with social commitments.[8]

Work life is almost always affected. Some patients are able to continue working during treatment, especially if their employer offers flexibility for medical appointments and accommodations for fatigue and side effects. However, many find they need to reduce their hours, take medical leave, or retire earlier than planned. This loss of work identity can be emotionally difficult, in addition to the financial stress it may create.[3]

Relationships with family and friends undergo changes. Some people rally around patients with tremendous support, while others may not know how to help or may withdraw because they feel uncomfortable. Roles within families often shift—a spouse who was never responsible for household finances may need to take over, or adult children may find themselves in caregiver roles for their parents.[18]

Emotional well-being fluctuates throughout the journey. Days or weeks of relative acceptance and calm may be interrupted by periods of anger, sadness, or fear, especially around the time of scans or when symptoms worsen. This emotional rollercoaster is normal and expected.[3]

Hobbies and leisure activities may need to be modified or given up temporarily or permanently. Someone who loved hiking may need to switch to gentle walks. A person who enjoyed cooking elaborate meals might need to rely more on simpler preparations or help from others. Finding new ways to enjoy life within current limitations becomes an important coping strategy.[3]

Many patients find that their priorities shift. Things that once seemed important may fade in significance, while relationships, meaningful experiences, and making the most of each day take center stage. Some people describe this as finding unexpected gifts within the cancer experience, though this perspective often takes time to develop.[3]

⚠️ Important
Every person’s experience with metastatic cancer is unique. Some patients maintain relatively good quality of life for extended periods, while others face more immediate limitations. Don’t compare your journey to others, and don’t hesitate to ask your healthcare team for support services like social workers, counselors, or support groups that can help you navigate the physical and emotional challenges you’re facing.

Support for Family: Understanding Clinical Trials and How to Help

Family members and loved ones play a crucial role in supporting someone with metastatic transitional cell carcinoma. Understanding what clinical trials are and how to help your loved one navigate their options can make a meaningful difference in their care and quality of life.[8]

Clinical trials are research studies that test new treatments or new ways of using existing treatments. For metastatic transitional cell carcinoma, clinical trials may evaluate new chemotherapy drugs, immunotherapy approaches, targeted therapies, or combinations of treatments. These studies are essential for advancing cancer care and may offer access to promising treatments before they become widely available.[8]

Understanding why clinical trials matter can help families feel more comfortable with this option. Because standard treatments for metastatic disease are limited in their ability to cure the cancer, clinical trials represent hope for better outcomes. Participation also contributes to knowledge that may help future patients. The medical community is actively working to improve treatments for metastatic urothelial cancer, with recent trials showing encouraging results.[13]

As a family member, you can help by learning about clinical trials alongside your loved one. Ask the oncology team if there are any trials available that might be appropriate for your family member’s specific situation. Factors that determine eligibility include the stage and type of cancer, previous treatments received, kidney function, overall health status, and whether the tumor has certain genetic features.[8]

Help with practical research by looking up trials together online. The National Cancer Institute and other reputable organizations maintain databases of ongoing clinical trials. When you find potentially relevant trials, write down questions to ask the medical team about eligibility, what the trial involves, potential benefits and risks, and practical considerations like travel requirements.[1]

Support your loved one in making informed decisions. Clinical trials are voluntary, and patients can withdraw at any time if they choose. Some patients feel excited about trying a new approach, while others prefer to stick with standard treatments. There is no right or wrong choice—what matters is that the decision aligns with your loved one’s values and goals for their care.[8]

Assist with the logistics of participating in a trial if your family member decides to enroll. This might include helping arrange transportation to appointments, keeping track of a more complex schedule of tests and treatments, managing medication schedules, and tracking side effects. Clinical trials often involve more frequent monitoring than standard treatment, so organizational support is valuable.[8]

Beyond clinical trials, there are many other ways families can provide meaningful support. Accompany your loved one to medical appointments when possible, taking notes and helping remember what was discussed. Healthcare visits can be overwhelming, and having another set of ears helps ensure important information isn’t missed.[18]

Provide practical help with daily tasks. As fatigue and symptoms increase, assistance with grocery shopping, meal preparation, housework, yard work, and transportation becomes increasingly valuable. Don’t wait to be asked—most patients hesitate to request help even when they desperately need it. Instead, offer specific assistance: “I’m going to the store on Tuesday. What can I pick up for you?” is more helpful than “Let me know if you need anything.”[18]

Emotional support is equally important. Listen without trying to fix everything or offer false reassurances. Sometimes your loved one needs to express fear, anger, or sadness without being told to “stay positive.” Simply being present and acknowledging that this is incredibly difficult can be deeply comforting.[18]

Learn about the disease and treatments so you can better understand what your family member is experiencing. This article and other reputable resources can help you become a more informed and effective support person. However, be careful not to overwhelm your loved one with information they haven’t asked for or treatment suggestions that might undermine their confidence in their medical team.[18]

Take care of yourself as well. Supporting someone with metastatic cancer is emotionally and physically demanding. You cannot pour from an empty cup. Make sure you have your own support system, whether that’s other family members, friends, a counselor, or a support group for caregivers. Many cancer centers offer support programs specifically for family members.[18]

Help your loved one stay connected with life beyond cancer. Encourage activities they enjoy when they have the energy. Help maintain social connections. Create opportunities for laughter and normal conversation. While cancer is a major part of life right now, helping your family member preserve their identity beyond their diagnosis is a gift.[18]

Finally, respect your loved one’s autonomy and wishes. They remain the decision-maker about their care, even if you disagree with their choices. Your role is to support, inform, and advocate for their preferences, not to take over or push your own agenda.[18]

💊 Registered drugs used for this disease

List of officially registered medicines that are used in the treatment of this condition, based only on the provided sources:

  • Avelumab – An immune checkpoint inhibitor used as maintenance therapy after platinum-based chemotherapy, shown to improve overall survival and progression-free survival in patients with platinum-responsive metastatic urothelial cancer
  • Enfortumab vedotin – An antibody-drug conjugate that, when combined with pembrolizumab, has shown significant improvements in overall survival, progression-free survival, and overall response rate in previously untreated metastatic urothelial cancer
  • Pembrolizumab – A PD-1 immune checkpoint inhibitor used both as single-agent therapy in cisplatin-ineligible patients and in combination with enfortumab vedotin for first-line treatment of metastatic disease
  • Nivolumab – A PD-1 immune checkpoint inhibitor that, when combined with gemcitabine-cisplatin chemotherapy, demonstrated significant extension in median overall survival and progression-free survival
  • Erdafitinib – A targeted FGFR inhibitor for patients with metastatic urothelial cancer and FGFR alterations, resulting in significantly longer overall survival than chemotherapy after previous immune checkpoint inhibitor treatment
  • Cisplatin – A platinum-based chemotherapy drug that remains the standard of care for first-line treatment of metastatic urothelial cancer when combined with other agents
  • Carboplatin – A platinum-based chemotherapy alternative used for patients ineligible for cisplatin
  • Gemcitabine – A chemotherapy drug commonly used in combination with cisplatin or carboplatin for metastatic disease

Ongoing Clinical Trials on Transitional cell carcinoma metastatic

  • Study on Nivolumab and Ipilimumab for Patients with Advanced Urothelial Cancer After Initial Chemotherapy

    Not recruiting

    1 1 1
    Investigated drugs:
    Spain

References

https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq

https://pmc.ncbi.nlm.nih.gov/articles/PMC1475968/

https://my.clevelandclinic.org/health/diseases/6239-transitional-cell-cancer

https://www.cancerresearchuk.org/about-cancer/upper-urinary-tract-urothelial-cancer

https://healthy.kaiserpermanente.org/health-wellness/health-encyclopedia/he.transitional-cell-cancer-of-the-renal-pelvis-and-ureter-treatment-pdq%C2%AE-treatment-patient-information-nci.ncicdr0000343585

https://www.ncbi.nlm.nih.gov/books/NBK66010/

https://www.aacr.org/patients-caregivers/cancer/transitional-cell-cancer-of-the-renal-pelvis-and-ureter/transitional-cell-cancer-of-the-renal-pelvis-and-ureter-treatment-pdq/

https://emedicine.medscape.com/article/281484-treatment

https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq

https://www.ncbi.nlm.nih.gov/books/NBK66010/

https://emedicine.medscape.com/article/281484-treatment

https://my.clevelandclinic.org/health/diseases/6239-transitional-cell-cancer

https://www.nature.com/articles/s41585-024-00872-0

https://www.cancer.gov/types/kidney/hp/transitional-cell-treatment-pdq

https://www.mayoclinic.org/diseases-conditions/bladder-cancer/diagnosis-treatment/drc-20356109

https://my.clevelandclinic.org/health/diseases/6239-transitional-cell-cancer

https://www.cancer.gov/types/kidney/patient/transitional-cell-treatment-pdq

https://www.cancercare.org/publications/417-caregiving_for_a_loved_one_with_bladder_cancer

https://www.cancer.org/cancer/types/bladder-cancer/after-treatment/follow-up.html

https://www.cancer.org.au/cancer-information/types-of-cancer/rare-cancers/upper-tract-urothelial-cancer

https://www.cancerresearchuk.org/about-cancer/upper-urinary-tract-urothelial-cancer

https://www.cancercare.org/publications/326-treatment_update_bladder_cancer

https://bladdercancercanada.org/en/patients/educational-resources/guidebooks/guidebook-translations/metastatic-bladder-cancer-patient-guide/

https://medlineplus.gov/diagnostictests.html

https://www.questdiagnostics.com/

https://www.healthdirect.gov.au/diagnostic-tests

https://www.who.int/health-topics/diagnostics

https://www.yalemedicine.org/clinical-keywords/diagnostic-testsprocedures

https://www.nibib.nih.gov/science-education/science-topics/rapid-diagnostics

https://www.health.harvard.edu/diagnostic-tests-and-medical-procedures

FAQ

Can metastatic transitional cell carcinoma be cured?

Cure is usually not possible with currently available treatments when transitional cell carcinoma has metastasized to distant organs. More than 90% of patients can be cured if the cancer is caught when it’s superficial and confined to the renal pelvis or ureter, but once the tumor has penetrated through the urothelial wall or spread to distant sites, cure becomes extremely unlikely. However, in rare cases, treatment of metastatic disease may result in a cure. The focus of treatment for metastatic disease is on prolonging survival, controlling symptoms, and maintaining quality of life.

Where does transitional cell carcinoma typically spread?

Transitional cell carcinoma typically spreads first to the pelvic lymph nodes and then to visceral organs including the lungs, liver, and bones. In some cases, particularly after patients have received systemic chemotherapy, the cancer may also spread to the brain. Less commonly, it can spread to unusual locations such as soft tissue, as documented in one case where a patient developed metastatic masses in the shoulder area.

What is the life expectancy with metastatic transitional cell carcinoma?

Median overall survival for metastatic urothelial cancer treated with standard cisplatin-based chemotherapy is approximately 14 months. However, this is an average and individual outcomes vary considerably based on factors such as tumor grade, number and location of metastases, overall health, kidney function, age, and response to treatment. Some patients live longer than the median, while others have a shorter survival time. Recent advances in treatment, including immunotherapy and targeted therapies, are working to improve these outcomes.

What treatments are available for metastatic transitional cell carcinoma?

Treatment options include chemotherapy (commonly cisplatin or carboplatin combined with gemcitabine), immunotherapy with checkpoint inhibitors (such as pembrolizumab, nivolumab, and avelumab), antibody-drug conjugates (such as enfortumab vedotin), and targeted therapy with FGFR inhibitors (such as erdafitinib) for patients whose tumors have specific genetic alterations. Recent clinical trials have shown that combinations of these treatments—such as enfortumab vedotin with pembrolizumab, or nivolumab with chemotherapy—can significantly improve outcomes compared to chemotherapy alone. Treatment choice depends on kidney function, previous treatments received, tumor characteristics, and overall health.

Why are so many patients with metastatic disease ineligible for the best chemotherapy?

Up to 50% of patients with metastatic urothelial cancer cannot receive cisplatin-based chemotherapy, which is considered the most effective chemotherapy regimen, because their kidneys are not functioning well enough to safely handle this medication. Cisplatin can be toxic to the kidneys, and patients who already have compromised kidney function—either from the cancer itself, previous treatments including surgery, or other health conditions—are at high risk for further kidney damage. For these patients, alternative treatments include carboplatin-based chemotherapy or immunotherapy with checkpoint inhibitors.

🎯 Key takeaways

  • Metastatic transitional cell carcinoma occurs when cancer has spread from the urinary tract to distant organs like lymph nodes, lungs, liver, or bones, and cure is usually not possible with current treatments
  • The goal of treatment shifts from cure to prolonging life, controlling symptoms, and maintaining quality of life—helping patients live as well as possible for as long as possible
  • Median survival with standard chemotherapy is about 14 months, but this varies greatly among individuals and newer treatments are improving outcomes
  • Half of patients cannot receive cisplatin, the most effective chemotherapy, because their kidneys cannot tolerate it—creating challenges in treatment selection
  • New treatment combinations including immunotherapy with antibody-drug conjugates or chemotherapy are showing significantly better results than older approaches
  • Living with metastatic disease affects every aspect of life—physical abilities, work, relationships, and emotional well-being—requiring comprehensive support
  • Clinical trials may offer access to promising new treatments and contribute to advancing care for future patients
  • Family support is crucial and includes helping with practical tasks, medical appointment logistics, decision-making about treatments including clinical trials, and emotional support